Slide 1: Jasper Therapeutics: Preliminary BEACON Results
1 Briquilimab is an investigative drug and is not approved for any indication Jasper Therapeutics: Preliminary BEACON Results NASDAQ: JSPR January 8 th , 2025
Slide 2: Safe Harbor Statements
2 Briquilimab is an investigative drug and is not approved for any indication Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statem ents. All statements other than stateme
Slide 3: Today's agenda and presenters
3 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Today’s agenda and presenters Title (Affiliation) Presenter Topic Chief Executive Officer Ronald Martell Opening Remarks and Topline Summary Chief
Slide 4: BEACON Preliminary Results Summary
4 Briquilimab is an investigative drug and is not approved for any indication 4 BEACON Preliminary Results Summary Edwin Tucker, MD, MRCP
Slide 5: Phase 1b/2a BEACON study in chronic spontaneous urticaria
5 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication 80mg 120mg 120mg 180mg 180mg 240mg 360mg 10 mg 40 mg Open Label Double - Blind Placebo - Controlled Screening/Eligibility • CSU diagnosis ≥ 6 mos.
Slide 6: Baseline demographics were generally balanced across the cohorts
6 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Baseline demographics were generally balanced across the cohorts Representative of a population of moderate to severe patients with CSU Pooled Pla
Slide 7: Briquilimab demonstrated deep reductions in UAS7 scores
7 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Briquilimab demonstrated deep reductions in UAS7 scores >25pt reduction in UAS7 noted in multiple dosing regimens ≥120mg Q8W regimens UAS7 Mean Ch
Slide 8: Dose dependent increase in patients achieving Complete Response
8 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Dose dependent increase in patients achieving Complete Response (UAS7=0) Complete responses noted at all doses ≥ 80mg Q8W Complete Response at Wee
Slide 9: Dose dependent increase in patients achieving Well Controlled Disease
9 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Dose dependent increase in patients achieving Well Controlled Disease 50% or more of patients achieved well - controlled disease 4 weeks post - do
Slide 10: All patients in the 240mg single-dose cohort maintained CR to 8 weeks
10 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication All patients in the 240mg single - dose cohort maintained CR to 8 weeks All patients achieving CR by week 2, with 66% Well Controlled at Week 12
Slide 11: Dose dependent UAS7 reductions observed over 26 weeks
11 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Dose dependent UAS7 reductions observed over 26 weeks Deeper UAS7 reductions observed in subsequent doses 0 10 20 30 40 0 1 2 3 4 5 6 7 8 9 10 11
Slide 12: Dose dependent reductions in serum tryptase
12 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Data cut - off 31 Dec 2024 Weeks Serum Tryptase ( n g/mL) 240mg SD 180mg pooled 120mg pooled Placebo 80mg Q8W LLOQ – 1.6 ng/mL 0 2 4 6 8 10 12 0
Slide 13: PK demonstrates early Cmax consistent with rapid onset of response
13 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Briquilimab PK demonstrates early Cmax consistent with rapid onset of response in patients with CSU • Preliminary PK data in patients with CSU in
Slide 14: Briquilimab was well tolerated and demonstrated a favorable safety profile
14 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Briquilimab was well tolerated and demonstrated a favorable safety profile >24 - week exposure for 10mg - 180mg doses, 12 - weeks for 240mg dose
Slide 15: Safety observations possibly related to c-Kit blockade were infrequent
15 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Safety observations possibly related to c - Kit blockade were infrequent and generally limited to low grade events Majority resolved during repea
Slide 16: Neutrophil counts generally remained stable
16 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication 0 2 4 6 8 10 12 14 16 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 240mg SD 180mg Q8W 120mg Q8W Weeks Mean Neutrophils (10 9 /L) Placebo Data cut - o
Slide 17: Preliminary BEACON results demonstrate rapid, deep and durable responses
17 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Preliminary BEACON study results demonstrate briquilimab achieved rapid, deep and durable responses in patients with moderate to severe CSU • Par
Slide 18: Efficacy, safety and PK informs optimal biologic dose selection
18 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Efficacy, safety and PK informs an optimal biologic dose selection for briquilimab CSU registrational program expected to be initiated in 2H 2025
Slide 19: Briquilimab for Chronic Urticaria
19 Briquilimab is an investigative drug and is not approved for any indication 19 Briquilimab for Chronic Urticaria Thomas B Casale, MD Prof of Medicine and Pediatrics, University of South Florida
Slide 20: Moderate-to-severe CSU impact on patients
20 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Severe CSU Moderate CSU Presentation Persistent or severe full - body hives 3 - 5 mod - severe flair - ups weekly UAS7 28+ Severe itch and 50+ wh
Slide 21: Preliminary BEACON data show deep and durable efficacy with favorable safety
21 Briquilimab is an investigative drug and is not approved for any indication Preliminary BEACON data in CSU show that briquilimab leads to deep and durable efficacy with a favorable safety profile 1 Moller C et al. Blood (2005) 2 Hundley TR et al. Blood (2004) 3. Arnold JN et al. Annu Rev Immunol
Slide 22: Upcoming Milestones and Closing Remarks
22 Briquilimab is an investigative drug and is not approved for any indication 22 Upcoming Milestones and Closing Remarks Ronald Martell
Slide 23: Positive preliminary BEACON results support registrational program in CSU
23 Briquilimab is an investigative drug and is not approved for any indication • Briquilimab demonstrated rapid onset of action with disease control observed as early as one week after initial dose • Complete responses were observed at doses as low as 80mg Q8W and 240mg dose demonstrated 100% Comple
Slide 24: Briquilimab has the potential to be a major immunology franchise
24 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Briquilimab has the potential to be a major immunology franchise by delivering control to millions of patients with mast - cell driven diseases •
Slide 25: Key milestones
25 Briquilimab is an investigative drug and is not approved for any indication Key milestones 2024 CSU CIndU Asthma Conferences PHASE 1B/2A = Completed = Future events/milestones 2025 2026 Registrational Phase 1b/2a a. Initial clinical data Clinical data all cohorts Open Label Extension Phase 1b/2a
Slide 26: Q&A
26 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is an investigative drug and is not approved for any indication Q&A
Slide 27: Jasper Therapeutics: Preliminary BEACON Results
27 Briquilimab is an investigative drug and is not approved for any indication Jasper Therapeutics: Preliminary BEACON Results NASDAQ: JSPR January 8 th , 2025